Robbie Marcus
Stock Analyst at JP Morgan
(4.02)
# 463
Out of 4,843 analysts
160
Total ratings
55.45%
Success rate
9.25%
Average return
Main Sectors:
Stocks Rated by Robbie Marcus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NPCE NeuroPace | Maintains: Overweight | $14 → $16 | $13.11 | +22.04% | 5 | May 14, 2025 | |
| CVRX CVRx, Inc. | Downgrades: Underweight | $15 → $7 | $6.80 | +2.94% | 6 | May 9, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Overweight | $128 → $105 | $93.34 | +12.49% | 6 | May 6, 2025 | |
| IART Integra LifeSciences Holdings | Maintains: Underweight | $24 → $12 | $12.68 | -5.36% | 6 | May 6, 2025 | |
| INSP Inspire Medical Systems | Maintains: Overweight | $235 → $195 | $138.25 | +41.05% | 5 | May 6, 2025 | |
| CNMD CONMED | Maintains: Neutral | $70 → $58 | $57.69 | +0.54% | 7 | May 1, 2025 | |
| RXST RxSight | Downgrades: Underweight | $40 → $17 | $16.22 | +4.81% | 5 | Apr 4, 2025 | |
| MMSI Merit Medical Systems | Initiates: Overweight | $120 | $94.56 | +26.90% | 1 | Mar 28, 2025 | |
| COO The Cooper Companies | Maintains: Overweight | $120 → $110 | $79.96 | +37.57% | 4 | Mar 7, 2025 | |
| BAX Baxter International | Maintains: Neutral | $38 → $36 | $30.70 | +17.26% | 17 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $445 | $382.35 | +16.39% | 9 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $575 → $675 | $555.75 | +21.46% | 5 | Jan 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $12 → $13 | $6.56 | +98.17% | 3 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $110 | $104.50 | +5.26% | 13 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $330 | $323.58 | +1.98% | 4 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $32 | $17.03 | +87.90% | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $40 | $34.07 | +17.41% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $78 | $77.73 | +0.35% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $85 | $84.86 | +0.16% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $71.53 | +25.82% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $53 → $50 | $32.05 | +56.01% | 2 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $8 | $5.86 | +36.64% | 2 | May 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $284 → $250 | $265.53 | -5.85% | 9 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $16 | $8.93 | +79.27% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $8 → $7 | $6.53 | +7.20% | 13 | Nov 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $15 → $17 | $11.72 | +45.05% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $125 → $118 | $132.85 | -11.18% | 5 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $116 → $156 | $142.24 | +9.67% | 2 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $130 → $105 | $82.41 | +27.41% | 11 | Dec 17, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $40 | $94.87 | -57.84% | 2 | May 5, 2020 |
NeuroPace
May 14, 2025
Maintains: Overweight
Price Target: $14 → $16
Current: $13.11
Upside: +22.04%
CVRx, Inc.
May 9, 2025
Downgrades: Underweight
Price Target: $15 → $7
Current: $6.80
Upside: +2.94%
Zimmer Biomet Holdings
May 6, 2025
Maintains: Overweight
Price Target: $128 → $105
Current: $93.34
Upside: +12.49%
Integra LifeSciences Holdings
May 6, 2025
Maintains: Underweight
Price Target: $24 → $12
Current: $12.68
Upside: -5.36%
Inspire Medical Systems
May 6, 2025
Maintains: Overweight
Price Target: $235 → $195
Current: $138.25
Upside: +41.05%
CONMED
May 1, 2025
Maintains: Neutral
Price Target: $70 → $58
Current: $57.69
Upside: +0.54%
RxSight
Apr 4, 2025
Downgrades: Underweight
Price Target: $40 → $17
Current: $16.22
Upside: +4.81%
Merit Medical Systems
Mar 28, 2025
Initiates: Overweight
Price Target: $120
Current: $94.56
Upside: +26.90%
The Cooper Companies
Mar 7, 2025
Maintains: Overweight
Price Target: $120 → $110
Current: $79.96
Upside: +37.57%
Baxter International
Feb 21, 2025
Maintains: Neutral
Price Target: $38 → $36
Current: $30.70
Upside: +17.26%
Jan 29, 2025
Maintains: Overweight
Price Target: $420 → $445
Current: $382.35
Upside: +16.39%
Jan 24, 2025
Maintains: Overweight
Price Target: $575 → $675
Current: $555.75
Upside: +21.46%
Dec 17, 2024
Upgrades: Neutral
Price Target: $12 → $13
Current: $6.56
Upside: +98.17%
Dec 16, 2024
Maintains: Overweight
Price Target: $100 → $110
Current: $104.50
Upside: +5.26%
Dec 12, 2024
Maintains: Overweight
Price Target: $280 → $330
Current: $323.58
Upside: +1.98%
Nov 5, 2024
Initiates: Overweight
Price Target: $32
Current: $17.03
Upside: +87.90%
Oct 30, 2024
Maintains: Overweight
Price Target: $30 → $40
Current: $34.07
Upside: +17.41%
Oct 25, 2024
Maintains: Neutral
Price Target: $72 → $78
Current: $77.73
Upside: +0.35%
Oct 25, 2024
Maintains: Neutral
Price Target: $75 → $85
Current: $84.86
Upside: +0.16%
Sep 9, 2024
Initiates: Neutral
Price Target: $90
Current: $71.53
Upside: +25.82%
Aug 8, 2024
Maintains: Neutral
Price Target: $53 → $50
Current: $32.05
Upside: +56.01%
May 8, 2024
Downgrades: Neutral
Price Target: $15 → $8
Current: $5.86
Upside: +36.64%
Feb 23, 2024
Downgrades: Neutral
Price Target: $284 → $250
Current: $265.53
Upside: -5.85%
Dec 20, 2023
Maintains: Neutral
Price Target: $10 → $16
Current: $8.93
Upside: +79.27%
Nov 8, 2023
Maintains: Underweight
Price Target: $8 → $7
Current: $6.53
Upside: +7.20%
Feb 23, 2023
Maintains: Neutral
Price Target: $15 → $17
Current: $11.72
Upside: +45.05%
Oct 20, 2022
Maintains: Overweight
Price Target: $125 → $118
Current: $132.85
Upside: -11.18%
Jan 27, 2022
Maintains: Overweight
Price Target: $116 → $156
Current: $142.24
Upside: +9.67%
Dec 17, 2021
Downgrades: Neutral
Price Target: $130 → $105
Current: $82.41
Upside: +27.41%
May 5, 2020
Maintains: Neutral
Price Target: $55 → $40
Current: $94.87
Upside: -57.84%